Original ArticleSquamous cell carcinoma of the thyroid: outcome of treatment in 16 patients
References (16)
- et al.
Squamous cell carcinoma of the thyroid gland
Am J Surg
(1988) - et al.
Phase II evaluation of accelerated radiotherapy for anaplastic thyroid carcinoma
Radiother Oncol
(1999) - et al.
Chemotherapy for thyroid cancer
Radiother Oncol
(1987) - et al.
Atlas of Tumour Pathology, Third Series, Fascicle 5: Tumours of the Thyroid Gland
Armed Forces Institute of Pathology
(1992) Primary squamous cell carcinoma of the thyroid gland: report of a case and review of the literature
Am Surg
(1964)- et al.
Canadian survey of thyroid cancer
Can Med Assoc J
(1985) - et al.
Primary squamous carcinoma of the thyroid—a case report
J Laryngol Otol
(1993) - et al.
Squamous cell carcinomas and adenosquamous carcinomas originating from the thyroid gland
Cancer
(1980)
Cited by (61)
Primary squamous cell carcinoma of thyroid with a novel BRAF mutation and High PDL-1 expression: A case report with treatment implications and review of literature
2020, Pathology Research and PracticeCitation Excerpt :Immunohistochemistry (IHC) reveals SCC-Ts positive for pancytokeratin, CK5/6, p63, p40 and PAX-8 with variable positivity for thyroglobulin and TTF-1; it is negative for CEA, calcitonin, and CD5 [5–8]. Radical surgical resection is the ideal treatment for these patients; however, complete resection is rarely achieved due to locally advanced disease at the time of diagnosis [4,9]. Additionally, SCC-T shows poor response to both radiation therapy and chemotherapy [4,10].
Squamous cell carcinoma of the thyroid gland in an elderly female presenting as a rapidly enlarging thyroid mass
2020, International Journal of Surgery Case ReportsCitation Excerpt :In some cases, squamous cell carcinoma of the thyroid gland may be associated with other types of well differentiated thyroid tumors, in such cases it is very difficult to conclude whether the tumor is arising de novo or as a result of a change in the histopathological characteristics of the well differentiated thyroid cancers [4]. The disease usually affects the elderly people, and most cases have an advanced disease at the time of presentation with invasion to the trachea, esophagus, and the vessels in the region of the neck, there may be distant metastasis at the time of the first presentation [1,5]. Patients usually present with a rapidly enlarging neck mass, which may be painful.
Primary squamous cell carcinoma of the thyroid in association with papillary thyroid cancer and Hashimoto thyroiditis
2018, Annales Francaises d'Oto-Rhino-Laryngologie et de Pathologie Cervico-FacialePrimary squamous cell carcinoma of the thyroid associated with papillary thyroid carcinoma and Hashimoto's thyroiditis
2018, European Annals of Otorhinolaryngology, Head and Neck DiseasesCitation Excerpt :Previous studies have reported discordant results concerning the efficacy of radiotherapy and chemotherapy. Some authors have suggested that surgery should be followed by radical radiotherapy to ensure the best chance of local tumour control [9,10]. Other prospective studies need to be conducted.
The treatment and outcome analysis of primary squamous cell carcinoma of the thyroid
2018, Auris Nasus LarynxCitation Excerpt :In both cases, there is a rapidly enlarging mass that is often associated with recurrent laryngeal nerve compression and pressure symptoms, including airway obstruction and dyspnea. The prognosis of SCC of the thyroid is generally very poor, with a low median survival period, due to the rapid growth and metastasis of the tumor [14]. In the current study, the overall median survival was only 8 months, while the rates of 1- and 2-year survival were 22.7% and 0%, respectively.
Primary squamous cell carcinoma of the thyroid: Case report and systematic review of the literature
2017, International Journal of Surgery Case ReportsCitation Excerpt :According to the inclusion/exclusion criteria, 52 full papers with reporting of 97 cases were screened. Some 17 publications with 48 cases without complete work-up, including CT-scan, panendoscopy, immunohistochemistry and double citations were excluded [6–22]. Finally, 35 papers and ours reporting on 50 patients were available for analysis [2–523–53].
- f1
Correspondence to: A. M. Cook, Dept. of Clinical Oncology, Royal Marsden Hospital, Downs Rd, Sutton, Surrey SM2 5PT, UK.